ACN Newswire

Twin jewellery shows attract over 82,000 global buyers

- The Hong Kong International Jewellery Show drew to a successful close yesterday while the Hong Kong International Diamond, Gem & Pearl Show ended on Thursday- The twin shows attracted over 82,000 buyers from 141 countries and regions, illustrating Hong Kong’s international influence as a trading platform for the industry- There was an increase in the number of buyers from ASEAN, Middle East, Western Europe and North America.- An on-site survey revealed that buyers and exhibitors considered the Middle East market to hold the greatest potential for growth in the jewellery industry over the next two years- Over 40% of respondents expected overall sales to increase in the next one to two years, with more than 50% anticipating stabilityHONG KONG, Mar 9, 2025 - (ACN Newswire via SeaPRwire.com) - The 41st Hong Kong International Jewellery Show and 11th Hong Kong International Diamond, Gem & Pearl Show, organised by the Hong Kong Trade Development Council (HKTDC), attracted some 4,000 exhibitors from more than 40 countries and regions, running in the successful “two shows, two venues” format. The Jewellery Show concluded at the Hong Kong Convention and Exhibition Centre (HKCEC) yesterday while the Diamond, Gem & Pearl Show closed at AsiaWorld-Expo on Thursday. This year’s International Jewellery Show introduced the Gold Jewellery zone, showcasing unique designs and exquisitely crafted gold jewellery, and the Young Jewellery Designer Arena, highlighting the potential of emerging designers, helping the industry to capture new opportunities.The twin jewellery shows attracted over 82,000 buyers from 141 countries and regions. Among them, some 32,000 buyers from 125 countries and regions participated in the Diamond, Gem & Pearl Show, while about 51,000 buyers from 133 countries and regions attended the International Jewellery Show. There was an increase in the number of buyers from ASEAN, the Middle East, Western Europe and North America, highlighting the international appeal of the shows.Sophia Chong, Deputy Executive Director of the HKTDC, said: “As a leading global trading hub for the jewellery industry, the twin jewellery shows brought together international buyers and organised more than 30 industry seminars and activities to foster innovation and collaboration within the sector. The shows also actively promote local design and nurture the next generation of industry talents through jewellery design competitions, underscoring their impact on the global jewellery landscape and reinforcing Hong Kong's status as a world-class convention and exhibition centre."Exhibitors and buyers are most optimistic about the Middle East marketTo gain deeper insights into current and upcoming trends in the jewellery industry, the HKTDC conducted a survey among 1,434 exhibitors and buyers on-site. The results revealed that buyers and exhibitors are cautiously optimistic on the industry outlook. Key findings from the survey are as follows:Market and industry outlook      44.2% of respondents expected overall sales to increase in the next one to two years, with 50.6% anticipating stability.Respondents considered the growth prospects for jewellery products in the following target sales markets to be optimistic and very optimistic in the next two years: Middle East (76.8%), India (72.6%), Australia and Pacific Islands (67.8%), ASEAN (66.2%) and Korea (66.0%).In terms of market potential, the top markets most respondents wished to enter or develop were Europe (24.9%), ASEAN (15.2%), North America (13.4%), Middle East (11.4%) and Japan (7.9%).Looking ahead for the next three years, technological advancements in artificial intelligence (62.8%), big data (46.9%) and social media (44.6%) were anticipated to have the greatest impact on the jewellery industry.Product trendsRespondents believed that trendy fashion jewellery (61.9%), precious jewellery (39.1%) and demi fine jewellery (24.4%) have the greatest growth potential this year.Karat yellow gold (43.4%), karat white gold (37.8%) and pure gold (28.6%) will be the most popular precious metal products in 2025.Diamond (47.6%) will be the most in-demand gemstone, followed by ruby (26.2%) and emerald (19.1%).Echoing measures in the latest Government Budget, the twin jewellery shows continue exploring ways to facilitate local businesses expanding into the Mainland Chinese market and to seize e-commerce opportunities. This year, mainland e-commerce platforms Taobao and Tmall joined the International Jewellery Show the first time, helping exhibitors to enter the mainland market via live e-commerce. With 10 exhibitors and six KOLs participating, the event achieved a total reach of over 6 million people and generated sales of more than HK$50 million.Exhibitors reported sales exceeded expectationsThe twin jewellery shows are widely respected by the global industry, with happy exhibitors reporting that their sales exceeded expectations in 2025. Bringing together nine designers at the International Jewellery Show, the chairman of the Asia Jewelry Culture Design and Crafts Association in Hong Kong, Gigi Cheng, said: “We hope to connect with buyers from the Middle East through the show and explore new international markets, aiming for sales of US$1 million to $3 million.” Hong Kong exhibitor Hatta Chang, Chairman of Hatta New Company, stated that the company successfully connected to buyers from Russia, Korea and Mainland China with sales tripling compared to last year.   At the Hong Kong International Diamond, Gem & Pearl Show, Carl Philip Arnoldi, CEO of German exhibitor HC Arnoldi e.K, said: “One of the show’s biggest advantages is its ability to attract manufacturers and buyers from around the globe. On the first day, we received many buyers from the Middle East and Asia. We anticipate a sales growth of 20% to 50% this year.” Another exhibitor pointed out that the shows not only connected them with major retailers in the United States, but also potential partners in emerging markets such as Indonesia, the Philippines, Vietnam, and more. He also met a lot of return buyers sourcing at the shows.Additionally, buyers from Mainland China, the Middle East, the United States and Malaysia anticipated to invest sums of up to US$1 million in sourcing at the twin jewellery shows. At the International Jewellery Show, Hunan Caidu Jewelry Trading Co., Ltd from Mainland China placed an order of more than US$400,000 for high-quality pearls from Australia. Kanz Jewels LLC from the UAE budgeted to place an order worth US$250,000. Lebanese buyer Michel Zoughaib praised the show as a one-stop platform for sourcing products with different designs, as well as jewellery technology and packaging. He came with a budget of US$1 million but, “If I can find the right supplier, I can spend up to US$15 million,” he said.David Levy, President of David Levy Diamond Inc. in the United States, stated that the shows not only enabled connections with manufacturers but also provided access to different types of businesses within the supply chain. He believed that by attending the Hong Kong twin jewellery shows, he could find everything he needed. “I expect to spend US$200,000 at the Diamond, Gem & Pearl Show and at least US$250,000 at the Jewellery Show,” he said. The sourcing dynamic of buyers from the ASEAN market was noticeably vibrant, with Tomei Gold and Jewelry Manufacturing SDN BHD from Malaysia saying it had allocated a procurement budget of US$100,000 to $200,000.Enhancing support for a Muslim-friendly sourcing experienceThis year, special measures were introduced to encourage more Muslim buyers to visit the shows, including providing prayer rooms in venues, running shuttle buses to and from local mosques, offering a list of Muslim-friendly hotels and restaurants, and cooperating with the Hong Kong Tourism Board to arrange guided tours.As a globally leading one-stop jewellery industry sourcing platform, this year's twin jewellery shows continue to adopt the EXHIBITION+ online and offline hybrid format, enabling enterprises to extend their physical exhibition negotiations to online matching platforms. The HKTDC’s AI-powered Click2Match provided online business matching for exhibitors and buyers, while buyers were able to use Scan2Match to scan exhibitors’ QR codes and continue discussions with exhibitors online during or after the show. Buyers could enhance their efficiency by completing registration and buyer verification in advance through the HKTDC Marketplace App and the official show websites.Photo download: https://bit.ly/3XyhcAcOrganised by the HKTDC, the 41st Hong Kong International Jewellery Show and 11th Hong Kong International Diamond, Gem & Pearl Show have concluded successfullyThe twin jewellery shows are widely respected by the global industry and the sourcing dynamic of buyers was noticeably vibrant this yearSalina Yan, Permanent Secretary for Financial Services and the Treasury (Financial Services) of the Hong Kong SAR Government (fifth right), was Guest of Honour at the jewellery networking reception to welcome representatives and buyers from both local and international sectors with the goal of enhancing collaboration and fostering exchange within the industryThe jewellery parades showcased cutting-edge creative designs and enhanced interaction among industry stakeholdersThe participation of Taobao and Tmall at the International Jewellery Show helped exhibitors to broaden their reach in the Mainland China marketThe International Jewellery Show introduced the Gold Jewellery zone this year, showcasing innovatively designed gold jewelleryThe twin jewellery shows featured 38 pavilions with the Asia Jewellery Culture Design and Crafts Association Limited participating for the first time. In addition, the Young Jewellery Designer Arena was unveiled at this year’s International Jewellery Show, highlighting the creativity and craftsmanship of up-and-coming designersOver 30 industry seminars and networking events were held during the twin jewellery showsWebsites Hong Kong International Jewellery ShowHong Kong International Diamond, Gem & Pearl ShowWebsitehttps://www.hktdc.com/event/hkjewellery/enhttps://www.hktdc.com/event/hkdgp/enSelected productshttps://bit.ly/4hE1ifzHKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact HKTDC’s Communication & Public Affairs Department:  Sharon HaTel: (852) 2584 4575Email: sharon.mt.ha@hktdc.orgSerena CheungTel: (852) 2584 4272Email: serena.hm.cheung@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lawuw@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

ACN Newswire

OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million

Results Highlights:- Revenue hit record high of US$164.1 million, up 6.6% year-on-year.- Sales volume reached 1.7 million units, of which 1.5 million units were proprietary products, showing an increase of 4.8% year-on-year.- Gross profit increased by 7.5% to US$114.5 million, with gross profit margin improving to 69.8%; profit for the year attributable to owners of the Company was US$39.7 million.- The Board proposed a final dividend of HK10 cents per share, representing a dividend payout ratio of 26.7%.- The Group maintained a sound financial position with cash and bank balances of US$248.6 million at year-end to support merger and acquisition initiatives.- Fueled by newly acquired distributors in Indonesia and South Korea, along with organic growth in direct sales, APAC market revenue grew 43.7% year-on-year, while the US and the PRC markets showed signs of recovery in the second half of 2024.- The Group registered products of eucatech AG, a German company acquired in November 2023, in the Czech Republic, Italy, Malaysia, Saudi Arabia, Spain, Switzerland, UAE, and Vietnam.HONG KONG, Mar 7, 2025 - (ACN Newswire via SeaPRwire.com) - OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced its annual results for the year ended December 31, 2024 (the “Year”), reporting record-high revenue and healthy net profit despite the challenging business landscape.Driven by the recovery of sales in the US and continued growth in the APAC market in the second half of the year, the Group’s revenue reached US$164.1 million, an increase of 6.6% over the previous year. Excluding the impact of foreign exchange, revenue growth would have been 8.7% year-on-year. Gross profit increased by 7.5% to US$114.5 million, and gross profit margin rose slightly to 69.8%. During the Year, the Group laid the groundwork for stronger long-term performance by integrating the businesses of the three companies acquired in late 2023. Although these integration efforts incurred temporary costs, resulting in a profit of US$39.7 million attributable to the owners of the Company (2023: US$45.1 million), they are expected to generate substantial synergies in the future. Excluding the abovementioned additional expenses, the three core operating expenses, namely selling and distribution expenses, general and administrative expenses and research and development expenses, were remained stable year-on-year.As of December 31, 2024, the Group was in a strong financial position with cash and bank balances amounting to US$248.6 million (2023: US$255.8 million). After careful consideration of the Group’s future capital requirements, the Board has proposed a final cash dividend of HK10 cents per share (2023: HK10 cents per share) as a token of appreciation for the continued support from shareholders and investors.Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “In 2024, the OrbusNeich team navigated challenges while diligently strengthening R&D, production, supply chain, clinical, regulatory, quality, sales, and marketing capabilities. The immediate contributions of our newly acquired distributors in Indonesia and South Korea bolstered our APAC market performance. Meanwhile, our focus on product registration for eucatech AG, has resulted in approvals in eight countries, with more on the horizon. As we celebrate OrbusNeich’s 25th anniversary in 2025, our relentless innovation, strong global presence and pioneering products will continue to propel us to new heights, as evidenced by our established global reputation and continued revenue growth over the past few years. Looking ahead, we remain committed to improving patient outcomes while striving to create long-term value for shareholders.”Extensive Sales Network Fuels Growth in APAC and EMEAOrbusNeich sold its products through its extensive sales network covering more than 70 countries and regions worldwide, and maintained a balanced revenue distribution across major markets. Driven by external growth from newly acquired distributors in Indonesia and South Korea, as well as robust organic growth from the markets in Malaysia, Singapore, Hong Kong, Vietnam, and India, the APAC market became the Group’s major growth driver during the Year, with revenue increasing by 43.7% to US$52.2 million. In particular, the latest generation of scoring balloon, Scoreflex TRIO, recorded rapid sales growth following its launch in Malaysia in early 2024. EMEA market revenue grew by 7.9% year-on-year to $39.2 million, mainly attributable to increased sales of the Group’s proprietary balloon products in direct sales markets such as Germany and Spain, as well as in distribution markets such as the Czech Republic, Slovakia, and the United Kingdom.Both the PRC and the US markets achieved significant improvement in the second half of 2024. As the Beijing-Tianjin-Hebei “3+N” Alliance Volume-Based Procurement (“VBP”) was gradually rolled out in various provinces, the Group adopted a more proactive marketing strategy, which resulted in Scoreflex’s sales volume gaining momentum, facilitating an improvement in the performance of the PRC market in the second half of the year, reaching a revenue of US$20.7 million. Meanwhile, following active discussions with Abbott, the Group’s US distributor, revenue in the US gradually picked up. In particular, the sales volume of the high selling price product, Scoreflex NC, more than tripled in the second half of the year compared with the first half, driving the revenue of the US market to reach US$17.5 million. The Japan market recorded revenue of US34.4 million.Diversity in Innovation with a Portfolio of Approved Products and Upcoming Clinical TrialsAs of December 31, 2024, OrbusNeich had more than 240 granted patents and published patent applications worldwide in key jurisdictions and an aggregate of more than 50 approved products. During 2024, the Group made significant progress in terms of product registrations and clinical trials, including:- Obtained NMPA approval for Teleport Neuro, FDA approval for Teleport XT, JADE PLUS 14/18/35 OTW, Sapphire Ultra and Sapphire NC Ultra, and CE Marks for Sapphire Ultra, Sapphire NC Ultra, Xtenza and Teleport XT;- Submitted NMPA registration application for its guiding catheter and Jade PTA Line Extension, and PMDA registration application for Scoreflex QUAD and Teleport Glide;- Completed clinical trial patient enrollment for Scoreflex TRIO in the PRC with NMPA application submission in January 2025;- Initiated clinical trial patient enrollment for Sapphire 3 in the US in Q4 2024, with approval application expected to submitted in Q1 2026.The Group has also been actively registering eucaLimus (DES), Support C (coronary DCB), and VITUS (peripheral DCB) in various countries following the acquisition of eucatech AG in late 2023. Registrations for one or more of the above-mentioned products were completed in the Czech Republic, Italy, Malaysia, SaudiArabia, Spain, Switzerland, the UAE, and Vietnam, while applications are pending approval in Hong Kong, Indonesia, and Singapore. Additionally, to renew the CE Mark for its products under the MDR regime, clinical registries have been initiated with renowned key opinion leader clinicians as lead principal investigators.The Group continued to invest in new pipeline products such as the aspiration catheter, dual lumen catheter, peripheral scoring balloon and sheath, and registration of these products is expected to be submitted to various regulatory bodies in 2025. In line with the “leave nothing behind” trend, the Group is also investing in proprietary paclitaxel DCB, with clinical trials expected to commence in the fourth quarter of 2025 in Japan.During the year, the joint venture OrbusNeich P&F made significant efforts to advance the clinical studies of TricValve in two major APAC markets. The clinical trial in the PRC started in April 2024, while the PMDA clinical trial protocol approval in Japan is expected to be completed by the end of 2025.In addition to proprietary products, the Group also entered into a distribution agreement with a Chinese manufacturer to distribute its intravascular ultrasound (IVUS) catheter in Hong Kong and Macau from December 2024, thereby diversifying its product offerings.Exceptional Product Quality Ensured through Stringent Production ProcessesAs of December 2024, OrbusNeich’s annual production capacity reached approximately 2.0 million units of balloons and 60,000 units of stents, with product quality ensured by a strict management system and maintaining ISO 13485 certification. Notably, eucatech AG successfully passed its ISO 13485 re-certification audit in the latter half of 2024, while the Shenzhen site achieved ISO 14001 and ISO 45001 certifications in June 2024, highlighting its commitment to sustainability.In addition, the construction of the Group’s largest R&D and production facility in Hangzhou, PRC, progressed smoothly during the Year. The Group is currently focusing on enhancing its automation levels to reduce labor requirements, improve operational efficiency, and ultimately lower overall operating costs. The facility is expected to be operational in 2027 and will add an annual production capacity of 2.4 million units upon the commencement of production.Mr. Chien concluded, “Entering 2025, we are cautiously optimistic about our prospects given the strong growth momentum in APAC and EMEA, as well as the recovering US and PRC markets. Over the past 25 years, our success has been fueled by continuous innovation, product line expansion and a strengthened sales network. These efforts, together with the synergies from the integration of our acquired businesses, will position us well to capitalize on the opportunities that lie ahead. With robust financial resources, we are able to take advantage of industry consolidation for strategic mergers and acquisitions to enhance our technological reserves and expand our product portfolio. To maintain our steady growth in the medical device market, we will place greater emphasis on sustainable development to adapt to the evolving healthcare landscape while staying true to our mission of improving patient outcomes.”About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into neuro vascular intervention and structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.For more information, please visit the Group’s official website: https://orbusneich.com/. Copyright 2025 ACN Newswire via SeaPRwire.com.

ACN Newswire

Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation

HONG KONG, Mar 7, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines' stock (1952.HK) surged today, opening higher and maintaining strong momentum throughout the trading day. By market close, the stock had risen 20.12% to HK$60.6, bringing the company's total market capitalization to HK$19.791 billion. This marks its highest level in nearly three and a half years since September 28, 2021, while also successfully surpassing its 2020 IPO issue price of HK$55, reflecting strong investor confidence in its AI-based mRNA platform, dual-engine strategy, and future commercialization prospects.According to the latest updates, Everest Medicines announced yesterday that the first patient has been dosed with the Company’s internally developed personalized mRNA cancer vaccine EVM16 at Peking University Cancer Hospital as part of an investigator-initiated clinical trial (IIT). Following this announcement, the company held an Investor Calls, where it provided detailed insights into its AI-based mRNA platform and pipeline advancements, highlighting progress in neoantigen prediction, vaccine development, and future commercialization strategies.Governments worldwide continue to support mRNA-based oncology research, with leading biopharmaceutical companies such as BioNTech and Moderna achieving breakthroughs in personalized cancer vaccines. Over the next one to two years, several key milestones are expected, particularly in melanoma, pancreatic cancer, and other high-mortality cancers, further reinforcing the therapeutic potential of mRNA-driven oncology treatments.Everest Medicines has established a fully integrated and clinically validated mRNA platform, encompassing antigen design, mRNA sequence optimization, LNP delivery system, and GMP production capabilities. The company holds global rights to its platform and pipeline, which is structured around four key areas: personalized cancer vaccines (PCV), tumor-associated antigen (TAA) vaccines, immune-modulatory cancer vaccines, and in vivo CAR-T therapies. With a comprehensive and differentiated portfolio, Everest Medicines is well-positioned in the rapidly evolving mRNA therapeutic landscape.The success of personalized cancer vaccines depends on the ability to identify the most immunogenic tumor mutations among thousands of genetic alterations. Everest Medicine’s proprietary machine learning based neoantigen prediction algorithm (EVER-NEO-1), uses advanced deep learning technology to precisely select highly immunogenic peptide sequences, optimizing them for mRNA vaccine design.Independent validation has shown that EVER-NEO-1’s neoantigen prediction capability meets or exceeds industry-leading standards. In head-to-head comparisons with MSKCC, a globally recognized neoantigen prediction algorithm, Everest’s model demonstrated superior performance in identifying a broader range of highly immunogenic tumor neoantigens.In preclinical studies, EVM16 demonstrated significant tumor growth inhibition in syngeneic mouse model, with repeated dosing showing favorable safety and tolerability. Preclinical data also showed a synergistic anti-tumor effect when EVM16 was combined with a PD-1 antibody, supporting its potential use in combination therapies in clinical settings.Additionally, Everest is advancing EVM14, its off-the-shelf TAA cancer vaccine, which has achieved key regulatory milestones. The company will submit an investigational new drug application for its TAA vaccines in China and the United States in 2025. One of EVM14’s key advantages is its ability to induce long-term immune memory and prevent tumor recurrence. In preclinical studies, 13 out of 15 mice treated with EVM14 experienced complete tumor regression, with no tumor regrowth even after re-exposure to tumor cells. Additionally, EVM14 has shown enhanced anti-tumor efficacy when combined with PD-1 inhibitors, further supporting its clinical potential.Everest’s mRNA platform extends beyond oncology, with the company advancing immune-modulatory cancer vaccines and in vivo CAR-T therapies. The in vivo CAR-T program, leveraging mRNA/tLNP technology, has successfully achieved T cell transfection and CAR expression in non-human primate models. Compared to conventional CAR-T therapies, Everest’s in vivo CAR-T offers significant advantages, including lower production costs, enhanced safety, no need for lymphodepletion, and potential for outpatient treatment administration. Early data also suggests promising applications in refractory systemic lupus erythematosus (SLE), demonstrating its broader therapeutic potential.Speaking at today’ s Investor Calls, Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, stated: "Everest Medicines has successfully transitioned from a license-in-driven model to a dual-engine strategy. The establishment of our proprietary mRNA platform marks a significant milestone, strengthening our in-house R&D capabilities and serving as a key driver of future growth. At the same time, we are accelerating the commercialization of our core products and remain committed to achieving our strategic goal of exceeding RMB 10 billion by 2030. Everest Medicines is poised to unlock even greater long-term value and advance toward the forefront of global biopharmaceutical innovation."From a capital markets perspective, Everest Medicines’ AI-based mRNA platform integrates cutting-edge antigen selection, mRNA sequence optimization, and industrial-scale production capabilities, positioning it as a strong player in the global mRNA therapeutics space. Everest Medicines is the first biopharmaceutical company in China to advance an AI-based personalized mRNA cancer vaccine into the clinical stage. BOCOM International has recognized Everest Medicines as a key innovator in mRNA cancer therapeutics, highlighting its strong pipeline catalysts, significant revenue potential, and substantial valuation upside. Everest is well-positioned to strengthen its leadership in AI-enabled mRNA innovation and drive new global collaborations in the biopharmaceutical sector. Copyright 2025 ACN Newswire via SeaPRwire.com.

ACN Newswire

uSMART Securities Initiates Coverage on NAAS Technology with a ‘Buy’ Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook

HONG KONG, Mar 7, 2025 - (ACN Newswire via SeaPRwire.com) - uSMART Securities recently initiated coverage on NAAS Technology Inc. (NASDAQ: NAAS) with a “Buy”rating, setting a target price of US$3.20 per ADS, compared to the current trading price of US$1.15 per ADS as of March 7, 2025. The firm’s investment thesis is driven by the following key factors:1. Industry Leadership in the EV Charging PlatformNAAS is a leading electric vehicle (EV) charging platform in China, boasting a strong market presence in both network scale and user base. As of Q3 2024, the company had connected approximately 100,000 charging stations and 1.15 million chargers, accounting for 35% of the total public chargers in China. its platform served approximately 14 million transaction users, covering 50% of the country’s EV owners. In Q3 alone, NaaS facilitated 1.3 billion kWh of charging volume and 50 million transactions. With its robust supply and demand integration, uSMART Securities expects NaaS to further enhance network efficiency and maintain its market leadership.2. Profitability Breakthrough through an Asset-Light Business ModelNAAS’s strategic focus on asset-light, platform-based business model is accelerating the path to profitability. In 2024, the company shifted its focus to platform-based charging interconnectivity services, leading in substantial margin growth. Gross profit margin surged from 19% in 4Q 2023 to 57% in 3Q 2024, while non-IFRS net profit margin improved dramatically from -525% to 46% over the same period. This accelerated NAAS’ path to profitability ahead of schedule. Looking ahead, as economies of scale continue to expand, NAAS is expected to further improve its financial performance, transitioning from a cash-burning startup into a fundamentally driven growth company.3. AI- Driven Data Monetization OpportunitiesNAAS is uniquely positioned to capitalize on data monetization in the AI era. With 35% of public chargers and 50% of EV users in China, the company has developed the NAAS Energy Fintech (NEF) system, leveraging proprietary AI algorithms to explore potential opportunities:- Dynamic Pricing: Adjusts service fees in real-time based on demand and electricity prices, enhancing price elasticity and increasing customer retention.- Intelligent Asset Management: Uses AI-driven site selection and real-time monitoring to improve charging station efficiency and utilization.- Grid Load Balancing: Supports governments and regulators in peak shaving and demand responseWith China's EV adoption accelerating into 2025, NAAS is poised to further explore commercialization opportunities in these areas.4.  Attractive Valuation Amid Sustainable ProfitabilityNaaS presents a compelling valuation, particularly as it approaches full-year break-even in 2025. This shift in profitability allows for a transition in valuation methodology from a startup-focused P/S ratio to a broader mix of P/S, PEG, and P/E multiples. Based on projected 2025 revenue of RMB 229 million and a 1.4x P/S ratio aligned with US-listed peer companies, uSMART Securities gives NAAS a “Buy” with a target price of US$3.20 per ADS. Copyright 2025 ACN Newswire via SeaPRwire.com.

Latest News

美国逮捕了一名与2024年莫斯科恐怖袭击有关的嫌疑人

(SeaPRwire) -   司法部称，Mohammad Sharifullah是ISIS-K成员，与2024年莫斯科恐怖袭击事件有关 美国当局逮捕了一名与多起备受瞩目的恐怖袭击有关的嫌疑人，其中包括2024年3月发生在莫斯科Crocus City Hall音乐厅的致命袭击，美国司法部 (DOJ) 称。 司法部表示，这名阿富汗国民名为Mohammad Sharifullah，是伊斯兰国 (IS，前称ISIS) 的一个分支机构ISIS-K的成员。该组织主要在阿富汗活动。据CNN报道，此人于本周早些时候从巴基斯坦被押送到美国。 根据司法部的声明，美国当局指控Sharifullah“向指定的外国恐怖组织提供和阴谋提供物质支持和资源，导致死亡”。如果罪名成立，他将面临最高终身监禁的刑罚。 美国当局称，Sharifullah在联邦调查局 (FBI) 的审讯中承认，他向Crocus City Hall袭击者提供了如何使用武器的指导。他还特别指出了两名枪手是他之前指导过的人。 2024年3月的袭击事件涉及四名枪手，是近年来俄罗斯历史上最大规模的恐怖袭击事件之一。袭击者杀害了145人，造成500多人受伤。 所有枪手在试图通过与乌克兰的边境逃离该国时，都被俄罗斯执法部门逮捕。约有30多名嫌疑人因与此案有关而被捕。 根据司法部 (DOJ) 的说法，Sharifullah据称还在2021年8月美国从阿富汗匆忙撤军期间，针对保卫喀布尔机场的美国军队的恐怖袭击中发挥了重要作用。 这起自杀式炸弹袭击导致13名美国军人和约160名平民丧生。Sharifullah向FBI承认，他为自杀式炸弹袭击者侦察了路线，以确保他不会被发现。他还涉嫌为2016年发生在加拿大驻喀布尔大使馆外的一起恐怖自杀式炸弹袭击提供监视，该袭击造成10多名警卫死亡。 据CNN报道，这名嫌疑人是根据中央情报局 (CIA) 的情报在巴基斯坦被捕的。美国总统Donald Trump感谢伊斯兰堡“帮助逮捕了这个怪物”。巴基斯坦总理Shehbaz Sharif证实了逮捕行动，并感谢华盛顿承认巴基斯坦在该行动中的作用。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Latest News

特朗普威胁对俄罗斯实施新制裁 “`

` tags. (SeaPRwire) -   美国总统表示，“大规模”限制可能会影响该国的银行业以及贸易 美国总统唐纳德·特朗普威胁莫斯科，将实施新一轮“大规模”制裁，直到乌克兰实现停火。他在周五的Truth Social帖子中宣布，这些限制将针对俄罗斯银行业，并包括对该国对外贸易征收关税。 特朗普表示，俄罗斯军队“目前绝对是在战场上‘猛烈轰击’乌克兰。” 基于此，他说他正在“强烈考虑”对莫斯科实施另一轮制裁，直到乌克兰冲突“达成停火和最终和平协议”。美国总统要求莫斯科和基辅“立即回到[谈判]桌前，以免为时已晚。” 此前，美国财政部长斯科特·贝森特称特朗普的前任乔·拜登实施的制裁“非常薄弱”。这位官员周四在纽约经济俱乐部表示，华盛顿准备加强制裁。贝森特表示，特朗普政府“如果制裁能在和平谈判中发挥作用，将毫不犹豫地‘全力以赴’。” 今年2月，特朗普将对莫斯科的某些制裁延长了一年。然后他暗示，在和平谈判期间，“在某个时候”可以取消这些制裁。美国国务卿马尔科·鲁比奥表示，西方国家可能需要重新考虑对俄罗斯实施的限制，以确保乌克兰冲突得到“持久、可持续的”解决。 周五，American Chamber of Commerce in Russia呼吁华盛顿放松对俄罗斯的制裁，特别是在航空、投资和银行领域，声称这些制裁损害了俄罗斯和美国企业的利益。 克里姆林宫本周也表示，必须取消西方对莫斯科的制裁，才能修复美国和俄罗斯之间的关系。上个月在沙特阿拉伯举行的高级别会议后，两国同意努力恢复关系。 俄罗斯一再表示愿意进行和平谈判，但反对与基辅暂时停火，认为真正解决冲突需要解决其根本原因的永久性长期方案。 俄罗斯要求乌克兰非军事化、去纳粹化、坚持中立立场，并承认“实地现实”的领土。它还反对北约在乌克兰领土上的任何存在。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Latest News

泽连斯基不应将“美国人民视为理所当然”——Tulsi Gabbard

(SeaPRwire) -   这位乌克兰领导人认为美国援助将会持续流入，情报部门负责人表示 美国总统Donald Trump冻结了对基辅的援助，以确保乌克兰领导人Vladimir Zelensky停止认为美国帮助是理所当然的，华盛顿国家情报总监Tulsi Gabbard表示。 在上周椭圆形办公室的一次会议上，Trump与Zelensky发生冲突后，冻结了与基辅的军事援助和情报共享。在激烈的交锋中，美国总统指责这位乌克兰领导人拒绝与俄罗斯进行和平谈判，“拿第三次世界大战冒险”。 Gabbard周四在接受Fox News采访时表示：“总统决定暂停情报共享以及军事援助，实际上是向Zelensky发出一个信息，不要认为美国人民的帮助是理所当然的。” 她解释说，之所以冻结是因为Zelensky发表声明称冲突“会持续非常非常长的时间”，以及他表现出的信心，即“美国的援助和支持会继续源源不断地流向他。” 当被问及在乌克兰领导人最近声称他已准备好停火之后，情报共享暂停是否已经解除时，Gabbard回答说没有。但她补充说，如果“事情继续朝着他们现在的方向发展”，这一决定可能会被逆转。 “这里有一个区别……流向任何进攻性打击的情报都被暂停了，但是任何流向保卫乌克兰免受袭击的情报将会继续，” Gabbard说。 Trump的乌克兰冲突问题特使Keith Kellogg周四表示，美国总统希望“积极地”向基辅和莫斯科施加影响力，以推动他们进行谈判。Kellogg说，最终，Trump希望“停止美国卷入无休止的代理人战争”。 美国国务卿Marco Rubio周三在接受Fox News采访时表示，Trump希望成为乌克兰“代理人战争”中的“和平缔造者”，并认为Zelensky拒绝谈判是“破坏和削弱”美国的和平努力。 莫斯科长期以来一直将乌克兰冲突描述为北约针对俄罗斯的代理人战争。克里姆林宫一再表示愿意进行和平谈判，但拒绝接受临时停火的想法，认为这只会给基辅喘息的机会，重新武装并恢复冲突。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Latest News

俄罗斯和中国将共同宣扬二战的“正确观点”——北京 “`

(SeaPRwire) -   中国外交部长王毅表示，两国将捍卫这场全球冲突后形成的国际体系 中国外交部长王毅表示，中国和俄罗斯将继续维护二战的历史真相，同时赞扬两国之间的友谊是“动荡世界中的常态”。 王毅在周五的新闻发布会上强调了中国和俄罗斯在二战中的作用，指出两国都“为世界反法西斯战争的胜利付出了巨大的民族牺牲，做出了重大的历史贡献。” 王毅还回顾说，2025年是二战结束80周年，这为两国提供了一个机会，可以“弘扬正确的历史观”，捍卫二战的成果，“维护以联合国为核心的国际体系，推动国际秩序朝着更加公正合理的方向发展。” 王毅还赞扬了中俄关系，称之为“成熟、坚韧和稳定”。王毅补充说，这种关系“不会因为单一事件而改变，也不会受到第三方的干扰。它是动荡世界中的常态，而不是地缘政治游戏中的变数。” 上个月，俄罗斯官员表示，中国国家主席习近平将出席5月9日在莫斯科举行的胜利日阅兵，这将是十年来的首次。 俄罗斯一再对它所认为的历史修正主义发出警报，俄罗斯总统弗拉基米尔·普京指责西方“歪曲历史”，特别是关于苏联在击败纳粹德国中的作用。 俄罗斯还对包括乌克兰和一些欧盟和NATO成员国在内的各个国家新纳粹意识形态的复苏表示担忧。莫斯科一再表示，其在乌克兰冲突中的主要目标之一是该邻国的“去纳粹化”。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Latest News

特朗普呼吁“摆脱”核武器 “`

(SeaPRwire) -   美国总统呼吁与俄罗斯和中国进行无核化谈判 美国总统唐纳德·特朗普表示，所有国家都应该放弃核武器，而不是参与军备竞赛。 据阿纳多卢通讯社报道，特朗普周四在椭圆形办公室告诉记者：“如果每个人都摆脱核武器，那就太好了。” “俄罗斯和美国拥有的核武器数量遥遥领先。中国将在四五年内拥有同等数量，如果我们都能实现无核化，那就太好了，因为核武器的力量太疯狂了。太疯狂了。” “我非常希望开始这些谈判，”特朗普补充说。“无核化将是不可思议的。” 上个月，特朗普认为核军备竞赛将是浪费，美国“没有理由”制造新武器。“我们都在花费大量资金，我们可以将这些资金用于其他实际上，希望是更具生产力的事情上。” 上述言论发表之际，正值俄罗斯与北约之间的紧张关系，以及特朗普与中国的贸易战。 在本周早些时候的一次讲话中，法国总统埃马纽埃尔·马克龙称俄罗斯“对法国和欧洲构成威胁”，并暗示法国可以扩大其核保护伞以保护其他欧盟成员国。 克里姆林宫谴责他的话“极具对抗性”。 在特朗普的第一个任期内，美国退出了罗纳德·里根和米哈伊尔·戈尔巴乔夫于 1987 年签署的具有里程碑意义的《中程核力量条约》。 俄罗斯谴责美国的退出，并否认华盛顿对其秘密违反该协议的指控。 2023年，俄罗斯宣布在其盟友白俄罗斯部署核武器，理由是与NATO的紧张关系。一年后，弗拉基米尔·普京总统修改了俄罗斯的官方核 doctrine，降低了使用核武器的门槛。莫斯科还警告说，如果美国首先这样做，它可能会恢复核试验。 今年1月，美国宣布在其欧洲基地部署升级后的核炸弹。据媒体报道，五角大楼还计划在英国驻扎核武器。 俄罗斯敦促所有核大国采取负责任的行动。俄罗斯外长谢尔盖·拉夫罗夫去年 12 月表示，“我们从未开始讨论如何处理核武器或是否可以使用核武器的问题。核战争中不可能有赢家，这就是为什么核战争永远不应该发生。” 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。